Literature DB >> 30282575

In Reply.

Gunnar H Heine.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30282575      PMCID： PMC6206395          DOI： 10.3238/arztebl.2018.0606b

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  5 in total

1.  The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: A nationwide cohort study in Taiwan.

Authors:  Yi-Hsin Chan; Yung-Hsin Yeh; Mei-Yun Hsieh; Chia-Yu Chang; Hui-Tzu Tu; Shang-Hung Chang; Lai-Chu See; Chang-Fu Kuo; Chi-Tai Kuo
Journal:  Int J Cardiol       Date:  2018-08-15       Impact factor: 4.164

2.  Warfarin Use Is Associated With Progressive Coronary Arterial Calcification: Insights From Serial Intravascular Ultrasound.

Authors:  Jordan Andrews; Peter J Psaltis; Ozgur Bayturan; Mingyuan Shao; Brian Stegman; Mohamed Elshazly; Samir R Kapadia; E Murat Tuzcu; Steven E Nissen; Stephen J Nicholls; Rishi Puri
Journal:  JACC Cardiovasc Imaging       Date:  2017-07-19

Review 3.  Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation.

Authors:  Gunnar H Heine; Vincent Brandenburg; Stephan H Schirmer
Journal:  Dtsch Arztebl Int       Date:  2018-04-27       Impact factor: 5.594

Review 4.  Self-monitoring and self-management of oral anticoagulation.

Authors:  Carl J Heneghan; Josep M Garcia-Alamino; Elizabeth A Spencer; Alison M Ward; Rafael Perera; Clare Bankhead; Pablo Alonso-Coello; David Fitzmaurice; Kamal R Mahtani; Igho J Onakpoya
Journal:  Cochrane Database Syst Rev       Date:  2016-07-05

5.  Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial.

Authors:  Sigrun Halvorsen; Dan Atar; Hongqiu Yang; Raffaele De Caterina; Cetin Erol; David Garcia; Christopher B Granger; Michael Hanna; Claes Held; Steen Husted; Elaine M Hylek; Petr Jansky; Renato D Lopes; Witold Ruzyllo; Laine Thomas; Lars Wallentin
Journal:  Eur Heart J       Date:  2014-02-20       Impact factor: 29.983
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.